Nurexone Biologic Stock Retained Earnings
| NRX Stock | 0.71 0.01 1.43% |
NurExone Biologic fundamentals help investors to digest information that contributes to NurExone Biologic's financial success or failures. It also enables traders to predict the movement of NurExone Stock. The fundamental analysis module provides a way to measure NurExone Biologic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NurExone Biologic stock.
| Last Reported | Projected for Next Year | ||
| Retained Earnings | -14.1 M | -14.8 M |
NurExone |
NurExone Biologic Company Retained Earnings Analysis
NurExone Biologic's Retained Earnings is a balance sheet account that refers to the portion of company income that is retained by the firm. In other words, it is a part of earnings that is not paid out as dividends or otherwise distributed to owners. Retained Earnings are calculated by adding net income to last period retained earnings and subtracting any dividends paid to owners.
More About Retained Earnings | All Equity Analysis
Retained Earnings | = | Beginning RE + Income | - | Dividends |
Current NurExone Biologic Retained Earnings | (14.06 M) |
Most of NurExone Biologic's fundamental indicators, such as Retained Earnings, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NurExone Biologic is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Retained Earnings shows how the firm utilizes its profits over time. In simple terms, investors can think of retained earnings as the amount of profit the company has reinvested in the business since its inceptions. However the methodology to make a decision over how much profit to retain is different between companies in different industries. For example, growing industries tend to retain more of their earnings than more matured industries as they need more assets investment to sustain their growth.
| Competition |
Based on the latest financial disclosure, NurExone Biologic has a Retained Earnings of (14.06 Million). This is 101.51% lower than that of the Biotechnology sector and 114.51% lower than that of the Health Care industry. The retained earnings for all Canada stocks is 100.15% higher than that of the company.
NurExone Retained Earnings Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NurExone Biologic's direct or indirect competition against its Retained Earnings to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NurExone Biologic could also be used in its relative valuation, which is a method of valuing NurExone Biologic by comparing valuation metrics of similar companies.NurExone Biologic is currently under evaluation in retained earnings category among its peers.
NurExone Fundamentals
| Return On Equity | -2.54 | ||||
| Return On Asset | -1.14 | ||||
| Current Valuation | 46.99 M | ||||
| Shares Outstanding | 70.84 M | ||||
| Shares Owned By Insiders | 4.75 % | ||||
| Number Of Shares Shorted | 32.31 K | ||||
| Price To Book | 13.94 X | ||||
| EBITDA | (4.09 M) | ||||
| Net Income | (3.64 M) | ||||
| Total Debt | 1.98 M | ||||
| Book Value Per Share | 0 X | ||||
| Cash Flow From Operations | (2.94 M) | ||||
| Short Ratio | 0.58 X | ||||
| Earnings Per Share | (0.11) X | ||||
| Target Price | 4.03 | ||||
| Beta | -0.091 | ||||
| Market Capitalization | 50.3 M | ||||
| Total Asset | 2.17 M | ||||
| Retained Earnings | (14.06 M) | ||||
| Working Capital | 74 K | ||||
| Net Asset | 2.17 M |
About NurExone Biologic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NurExone Biologic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NurExone Biologic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NurExone Biologic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NurExone Stock Analysis
When running NurExone Biologic's price analysis, check to measure NurExone Biologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NurExone Biologic is operating at the current time. Most of NurExone Biologic's value examination focuses on studying past and present price action to predict the probability of NurExone Biologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NurExone Biologic's price. Additionally, you may evaluate how the addition of NurExone Biologic to your portfolios can decrease your overall portfolio volatility.